New sleep apnea pill shows stronger results in post-menopausal women

Post-menopausal women with obstructive sleep apnea (OSA) could have a new oral treatment option on the horizon. A post hoc analysis of two phase 3 randomized controlled trials — SynAIRgy and LunAIRo — found that AD109, a once-daily tablet combining 2.3 mg aroxybutynin and 75 mg atomoxetine, significantly reduced OSA severity in post-menopausal women over 26 weeks. The results, presented at the CHEST 2026 Annual Meeting, are particularly notable given that OSA prevalence triples after menopause due to hormonal shifts that impair breathing and vascular function.

The analysis pooled data from 492 post-menopausal women and 807 men/non-menopausal individuals. Post-menopausal women on AD109 saw greater improvements across all key measures compared to both placebo and the non-menopausal group — though researchers caution the findings are exploratory and no formal interaction analysis was performed.

By the Numbers:

• 59.6% geometric mean reduction in AHI with AD109 vs. 16% with placebo in post-menopausal women
• 47.2% of post-menopausal women on AD109 achieved ≥50% AHI reduction vs. 20.2% on placebo
• 62.1% adjusted treatment difference in hypoxic burden for post-menopausal women vs. 43.6% in the non-menopausal group
• ~23% of both groups discontinued due to treatment-emergent adverse events; dry mouth was the most common side effect (45.8% in post-menopausal women)

Why it matters: For post-menopausal women — a group often underdiagnosed with OSA and frequently intolerant of CPAP therapy — an effective oral alternative could be meaningful. Researchers are calling for further sex-specific studies to better understand who benefits most.